ResMed Inc. (RMD)
| Market Cap | 31.41B |
| Revenue (ttm) | 4.58B |
| Net Income (ttm) | 958.38M |
| Shares Out | 146.91M |
| EPS (ttm) | 6.51 |
| PE Ratio | 33.27 |
| Forward PE | 26.86 |
| Dividend | $1.92 (0.90%) |
| Ex-Dividend Date | May 8, 2024 |
| Volume | 90,476 |
| Open | 216.00 |
| Previous Close | 216.84 |
| Day's Range | 213.63 - 217.55 |
| 52-Week Range | 132.24 - 237.26 |
| Beta | 0.64 |
| Analysts | Buy |
| Price Target | 212.30 (-0.71%) |
| Earnings Date | Apr 25, 2024 |
About RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics... [Read more]
Financial Performance
In 2023, ResMed's revenue was $4.22 billion, an increase of 18.02% compared to the previous year's $3.58 billion. Earnings were $897.56 million, an increase of 15.15%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for RMD stock is "Buy." The 12-month stock price forecast is $212.3, which is a decrease of -0.71% from the latest price.
News
S&P 500 Gains and Losses Today: Resmed Soars Amid Strong Demand for Sleep Devices
Although the latest Personal Consumption Expenditure (PCE) data showed inflation persisting in March, strong earnings reports from several big tech firms helped major U.S. equities indexes pop higher ...
ResMed Stock Soars After Strong Earnings. Wall Street Thinks It Can Do Even Better.
The medical devices company beat expectations for its fiscal third quarter.
ResMed tops quarterly profit estimates on strong demand for sleep apnea devices
ResMed beat Wall Street estimates for quarterly profit on Wednesday due to strong demand for its sleep apnea devices, sending shares 9% higher in extended trading.
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, ...
ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
ResMed announced the results of its 2024 Global Sleep Survey, uncovering a world in sleep crisis and encouraging people to discover their sleep superpowers
Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed's Smallest Full-Face CPAP Mask
Enhances sleep apnea therapy by combining the ease and comfort of an ultra-compact, under-the-nose full-face design with the effectiveness of a traditional over-the-nose full-face mask. Featuring the ...
ResMed's New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
Enhances availability of device therapy options, particularly for those who struggle with single pressure PAP therapy Part of Air11 Solutions, key features include Care Check-in, Personal Therapy Assi...
Three-Stock Lunch: SoFi, Warner Bros. Discovery and ResMed
Boris Schlossberg, BK Asset Management, joins 'Power Lunch' to discuss SoFi, Warner Bros. Discovery and ResMed.
ResMed beats estimates on strong sleep apnea device sales
ResMed beat Wall Street estimates for second-quarter revenue and profit on Wednesday, powered by strong demand for its respiratory devices used to treat sleep apnea.
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
ResMed says its masks to remain on market despite FDA classification
ResMed said its respiratory masks containing magnets will remain on the market even though the U.S. Food and Drug Administration classified a recall of the product as most serious as their use could c...
US FDA identifies recall of ResMed's respiratory devices as most serious
The U.S. Food and Drug Administration (FDA) on Thursday classified the recall of certain respiratory masks made by ResMed as most serious as their use could cause major injuries or death.
ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2024 on Wednesday,...
ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer and chair of the board, will present at the 42nd Annual J.P. Morgan Heal...
ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices
ResMed's masks with magnets are safe when used in accordance with the updated Instructions for Use ResMed's masks with magnets are safe when used in accordance with the updated Instructions for Use
ResMed Secures Significant Victory in Patent Fight Against New York University
SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced that it has secured a significant victory after the United States Patent Trial and Appeals Board (PTAB) invalidated ...
Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally
Published in the Journal of the American Medical Association Network Open, study estimates global COPD burden from 2020 through 2050 Study projects disproportionate growth in COPD among women and low...
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2024
Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
Jim Cramer is weighing out the risks of weight loss drugs
'Mad Money' host Jim Cramer takes a deep dive into the impact of obesity drugs on various sectors.
ResMed to Report First Quarter Fiscal 2024 Earnings on October 26, 2023
SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2024 on Thursday, O...
Will ResMed Stock Rebound To Its Pre-Inflation Shock Highs Of $300?
This compares with the Sharpe of 1.3 for the Trefis Reinforced Value portfolio.